Pinnacle Wealth Planning Services Inc. Purchases Shares of 25,439 Metagenomi, Inc. (NASDAQ:MGX)

Pinnacle Wealth Planning Services Inc. purchased a new stake in Metagenomi, Inc. (NASDAQ:MGX) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 25,439 shares of the company’s stock, valued at approximately $92,000. Pinnacle Wealth Planning Services Inc. owned about 0.07% of Metagenomi as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Peapod Lane Capital LLC acquired a new stake in shares of Metagenomi during the 4th quarter worth $1,268,000. Geode Capital Management LLC increased its holdings in shares of Metagenomi by 105.8% during the 3rd quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock worth $734,000 after buying an additional 173,796 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in shares of Metagenomi by 209.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company’s stock worth $296,000 after buying an additional 92,468 shares during the last quarter. Good Life Advisors LLC acquired a new stake in shares of Metagenomi during the 4th quarter worth $451,000. Finally, Fortitude Advisory Group L.L.C. acquired a new stake in shares of Metagenomi during the 4th quarter worth $273,000.

Metagenomi Price Performance

NASDAQ:MGX opened at $2.07 on Friday. The firm has a 50-day moving average of $2.68 and a two-hundred day moving average of $2.56. Metagenomi, Inc. has a 1-year low of $1.61 and a 1-year high of $12.10.

Analysts Set New Price Targets

A number of analysts have recently commented on MGX shares. Chardan Capital restated a “buy” rating and set a $15.00 price objective on shares of Metagenomi in a report on Wednesday, November 20th. HC Wainwright increased their price target on Metagenomi from $7.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, December 10th.

Metagenomi Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.